Volume 11 Issue 151
Published - 14:00 UTC 08:00 EST 12-Jun-2009 
Next Update - 14:00 UC 08:00 EST 13-Jun-2009

Editor: Susan K. Boyer, RN
© Vidyya.
All rights reserved.



Breast cancer drug helps patients with gastric cancer  

(12 June 2009: VIDYYA MEDICAL NEWS SERVICE) -- The breast cancer drug trastuzumab (Herceptin) has been shown to improve the survival of patients with advanced gastric cancer. The addition of trastuzumab to standard chemotherapy helped patients live longer than similar patients who received chemotherapy alone, researchers said at the ASCO annual meeting.

The phase III ToGA trial compared the two treatments in 594 patients whose tumors showed elevated levels of the protein HER2, which is the target of trastuzumab. Patients who received trastuzumab plus chemotherapy lived 13.8 months, compared with 11.1 months for those who received chemotherapy alone, said lead investigator Dr. Eric Van Cutsem of the University Hospital Gasthuisberg in Leuven, Belgium. The results translate into a 26 percent reduction in the risk of death.

Trastuzumab is the first targeted drug to improve overall survival for patients with gastric cancer in a phase III trial, he said. And while the survival benefit was small, he added, the findings represent a rare advance in gastric cancer.

The combination treatment was well tolerated and there were no unexpected side effects in the trastuzumab group, Dr. Van Cutsem said. The rate of congestive heart failure, which is routinely monitored in trials involving trastuzumab, was similar between the groups. The incidence of decreased ventricular ejection fraction (a measure of the heartís pumping ability) was 5.9 percent in the trastuzumab group compared with 1.1 percent in the chemotherapy-alone group. The reason for the low rate of cardiac effects, he said, may be because trastuzumab was not used in conjunction with anthracycline-based chemotherapy, which is how trastuzumab is often administered to breast cancer patients.

Return to Vidyya Medical News Service for 12 June 2009

© Vidyya. All rights reserved.

Information appearing on the Vidyya Medical News Service is not intended as a substitute for professional medical care. Seek professional medical help and follow your health care provider's advice.

Interested in subscribing to our daily e-mail newsletter? Send an email to Vidyya@vidyya.com with the word subscribe in the subject field.